Researchers Submit Patent Application, "Combination Therapy Using Bax Activator Agent", for Approval (USPTO 20230372307).
In: Pharma Business Week, 2023-12-14, S. 1806-1806
serialPeriodical
Zugriff:
A patent application has been submitted for a combination therapy using a Bax activator agent for the treatment of cancer. The therapy aims to target the deregulated apoptosis, or programmed cell death, that is characteristic of cancer cells. By activating the Bax protein and inhibiting anti-apoptotic proteins, the therapy aims to induce apoptosis in cancer cells. The patent application describes the pharmaceutical combination and methods of administering it to treat cancer. This research provides potential new options for cancer treatment, particularly for tumors that are resistant to current therapies. [Extracted from the article]
Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Combination Therapy Using Bax Activator Agent", for Approval (USPTO 20230372307).
|
---|---|
Zeitschrift: | Pharma Business Week, 2023-12-14, S. 1806-1806 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6675 (print) |
Schlagwort: |
|
Sonstiges: |
|